According to a report from Reuters, the President claimed that these drugs would cost $150 out-of-pocket. As of the time of ...

In today’s Pharmaceutical Executive Daily, we explore how antibody-drug conjugate collaborations are moving beyond oncology ...

As the pharmaceutical industry moves beyond rule-based omnichannel marketing, a new era of agentic systems is emerging, in which AI-powered agents collaborate with humans to orchestrate engagement, ...

EMD Serono's agreement with the US government aims to expand IVF therapy access for 10 million women, offering significant ...

Peptilogics Founder, CEO, Jonathan Steckbeck, explained that PLG0206 stands apart from current treatments, while the ...

Veradermics raised $150 million to advance VDPHL01, an oral minoxidil treatment for hair regrowth, through Phase III trials ...

Boehringer Ingelheim and AimedBio collaborate on ADC therapy targeting a protein involved in cancer growth, aiming to enhance ...

In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the ...

Learn what makes an AI roleplay solution actually move the needle in pharma field team performance. Lead with insight with ...

What impact will TrumpRx and other DTC programs have on drug availability? Jesse Mendelsohn: To be clear, anything that expands access to pharmaceutical ...

PE: How do you see the relationship between financial leadership and innovation evolving within rare disease biotech companies? Smith: You know, finance leaders have to be comfort ...

BioLamina CEO Klaus Langhoff-Roos discusses the challenges of scaling stem cell production from lab plates to bioreactors, ...